#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    B-cell small lymphocytic lymphoma Cervix carcinoma Polymyositis Congenital leptin deficiency Tourette's disorder Ewing's sarcoma Chemical burn Lymphoma Eosinophilic granulomatosis with polyangiitis Vulval cancer Prophylaxis against transplant rejection Albright's disease Ehlers-Danlos syndrome Epstein-Barr virus associated lymphoproliferative disorder Cutaneous T-cell lymphoma stage II More trials…

    Learn about Rare Diseases

    Osteosarcoma – Diagnostics Short-bowel syndrome – Treatment Wiskott-Aldrich syndrome – Diagnostics Soft tissue sarcoma – Diagnostics Langerhans cell sarcoma – Diagnostics Systemic sclerosis pulmonary – Life with Disease Chondrosarcoma – Diagnostics Antisynthetase syndrome – Basic Information Haemophagocytic lymphohistiocytosis – Diagnostics CADASIL – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Glucocorticoids Leniolisib Phosphate Pemetrexed Disodium Mannitol ANHYDROUS CALCIUM FOLINATE Entecavir IG-TREGS Lapatinib Neob Paclitaxel Albumin-Bound Dsimc Peppermint Oil Clarithromycin Atidarsagene Autotemcel ALLO-QUADCAR01-T Tinlarebant 10-1074-Ls Clonazepam M1P Dipotassium Salt Betula Pollen Extract More therapies…

    Learn about Your Condition

    Multifocal motor neuropathy Paraesthesia Sarcoma metastatic Breast angiosarcoma metastatic Laparotomy Dilated cardiomyopathy Immune system disorder Rabies Cancer fatigue Psychological trauma Asthma Macular oedema Cholangitis sclerosing Aphthous ulcer Hepatoblastoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myeloproliferative neoplasm

  • Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    • Myeloproliferative neoplasm
    • Primary myelofibrosis
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Apixaban
    • Rivaroxaban
    France

  • Study on Long-Term Safety of Pelabresib for Patients with Myelofibrosis or Essential Thrombocythemia

    Recruiting

    3 1 1
    Investigated Diseases:
    • Myeloproliferative neoplasm
    • Myelofibrosis
    Investigated Drugs:
    • 2-((4S)-6-(4-Chlorophenyl)-1-Methyl-4H-Benzo[C]Isoxazolo[4,5-E]Azepin-4-Yl)Acetamide Monohydrate
    Belgium Italy The Netherlands

  • Study on the Effects of Atorvastatin for Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Myeloproliferative neoplasm
    Investigated Drugs:
    • Atorvastatin
    Denmark

  • Anakinra for patients with myeloproliferative neoplasms resistant to cytoreductive therapy: a study to improve treatment response

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Myeloproliferative neoplasm
    Investigated Drugs:
    • Anakinra
    France

  • Study of Gandotinib for Patients with Myeloproliferative Neoplasms, Myelofibrosis, Essential Thrombocythemia, or Polycythemia Vera

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Myeloproliferative neoplasm
    • Essential thrombocythaemia
    • Myelofibrosis
    Investigated Drugs:
    • Gandotinib
    Austria Germany Spain

  • Study on the Safety and Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis and Myeloproliferative Neoplasms

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Myeloproliferative neoplasm
    • Myelofibrosis
    Investigated Drugs:
    • Navitoclax
    • Celecoxib
    • Ruxolitinib
    Bulgaria Croatia France Germany Italy Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!